The 2022 UK-Taiwan Digital Health Programme will offer valuable insights into Taiwan’s market and regulatory landscape, which, along with matchmaking events, will explore areas of joint interest, research, and linking to commercial partners in Taiwan.

Why Taiwan?

Joint R&D opportunities lie in Taiwan’s ICT strengths, as Taiwan excels in hardware development with a well-established and professional supply chain.

Taiwan’s leading ICT giants are now actively seeking investment and partnership opportunities and R&D projects as they focus on the healthcare industry as a path to diversification.

Taiwan is the world’s 21st largest economy and is a prime location for industry investment, partnerships, and licensing opportunities. Taiwan ranked #10 in the 2020 World Index of Healthcare Innovation, and pharmaceutical companies such as GSK and AstraZeneca have Taiwan clinical R&D centres.
 

The webinar will focus on Taiwan's market and regulatory landscape, including 3 main topics:

National Healthcare System
The Digital Health Market Landscape
The Regulatory Environment

It will be followed by a B2B matchmaking 7 - 11 March

Deadline to register is 9 February